PFM Health Sciences’s Allergan plc AGN Stock Holding History

PFM Health Sciences’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-314,700	Closed	-$2.52M	–	90
2015 Q3	$2.52M	Buy	+314,700	New	+$96.7M	0.07%	62

Other funds holding AGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PFM Health Sciences's AGN Position: Q1 2020 in Review

PFM Health Sciences sold out of Allergan plc (AGN) in Q1 2020, closing a stake of 281,548 shares — an estimated $53.8M sold.

PFM Health Sciences first reported a position in AGN in Q2 2013 and held it in 17 quarters. The position peaked at $299M in Q2 2019. 876 funds tracked by Wall St. Rank hold AGN as of Q1 2020.

PFM Health Sciences reported no remaining Allergan plc position as of Q1 2020 after selling out during the quarter.
PFM Health Sciences sold 281,548 Allergan plc shares in Q1 2020, an estimated $53.8M.
PFM Health Sciences first reported a position in Allergan plc in Q2 2013 and held it in 17 quarters.
PFM Health Sciences's Allergan plc position peaked at $299M in Q2 2019.
876 funds tracked by Wall St. Rank held Allergan plc as of Q1 2020.

Based on PFM Health Sciences's 13F filing for Q1 2020, filed 15 May 2020.